Alerta

一种微流控卡盒和蛋白标志物检测方法

Resumen de: CN122831030A

本申请公开一种微流控卡盒和蛋白标志物检测方法，该微流控卡盒包括依次串联连接的多个试剂储存腔、与最下游试剂储存腔连通的反应腔、设置于相邻腔室之间流道上的控制阀、与反应腔连通的流体转移单元以及与各试剂储存腔连通的通气孔。本申请的微流控卡盒通过外部磁铁引导磁珠依次穿过各腔室完成靶标捕获、清洗、链霉亲和素偶联和核酸连接，仅在最下游腔室与反应腔之间通过流体转移单元实现液体转移以复溶冻干试剂并进行核酸扩增和信号检测。结构简单，无需精密泵阀，降低了制造成本和操作复杂度。封闭式设计杜绝交叉污染，且通用性强，仅需更换检测抗体即可适配不同靶标蛋白。

基于CD9的PASC相关心血管系统症状风险评估应用

Resumen de: CN122833160A

本发明涉及生物医药技术领域，尤其是涉及基于CD9的PASC相关心血管系统症状风险评估应用。本发明提供了一种以CD9为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。

基于H2O2含量检测的神经退行性疾病进展评估方法及系统

Resumen de: CN122827656A

本发明涉及磁共振成像技术利用，公开了一种基于H2O2含量检测的神经退行性疾病进展评估方法及系统，方法包括以下步骤：对最常见的神经退行性疾病阿尔兹海默病转基因APP/PS1小鼠模型进行H2O2含量的在体动态监测，得到动态监测结果；设置若干个监测时间点；在每个监测时间点利用，结合所述VDMP‑CEST序列和非均匀采样法对所述患者进行扫描；扫描时采用针对H2O2优化的饱和脉冲参数；基于扫描得到的数据，利用基于水信号参考的CEST定量方法，定量每个监测时间点H2O2的CEST信号强度。

一种抗CXCL1的纳米抗体及其应用

Resumen de: CN120795145A

The invention belongs to the technical field of biological medicine, and particularly relates to an anti-CXCL1 nano antibody and application thereof. The nano antibody comprises a heavy chain variable region targeting CXCL1, and the heavy chain variable region is composed of FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4; the amino acid sequence of the nano antibody and any one of SEQ ID NO.1-49 have at least 70% of sequence identity. The nano antibody has the advantages of small molecular weight, small immunogenicity and better solubility and stability, is beneficial to basic research and clinical tests, has potential diagnosis and treatment prospects for tumors, autoimmune diseases and neurological diseases, and has good practical application value.

抗ＴＤＰ－４３抗体及びその使用

Resumen de: WO2025059486A1

The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).

可以分辨APOE4基因杂合子和纯合子的指尖血试纸条

Resumen de: CN122814900A

本发明公开了一种可以分辨APOE4基因杂合子和纯合子的指尖血试纸条。不仅可以用于快速检测受试人是否APOE ε4基因的携带者，而且还能进一步区分APOE ε4基因的携带者是杂合子还是纯合子。所述试纸条包括PVC底板，所述PVC底板上铺设有依次搭接的样本垫、滤血垫、结合垫、硝酸纤维层析垫和吸水垫；所述结合垫上涂有与抗人ApoE单克隆抗体结合的胶体金颗粒、彩色乳胶颗粒或荧光颗粒；所述硝酸纤维层析垫上靠近结合垫的一侧设有检测线T1和T2线、靠近吸水垫的一侧设有对照控制线C线，所述检测线T1线上涂有抗人ApoE4单克隆抗体，所述检测线T2线上涂有抗人ApoE多克隆抗体，所述对照控制线C线上涂有相应的抗IgG多克隆抗体。

一种单克隆抗体或其抗原结合片段及其制备方法与应用

Resumen de: CN122810244A

本发明公开了一种单克隆抗体或其抗原结合片段及其制备方法与应用。涉及生物医学技术领域。所述单克隆抗体或其抗原结合片段能够特异性结合DAP12蛋白，并且包含如SEQ ID NO：3至8所示的特定重链及轻链互补决定区序列；本发明提供的单克隆抗体或其抗原结合片段具有特异性强、灵敏度高、交叉反应低的特点，所述抗体及片段可广泛应用于蛋白质免疫印迹（Western Blot）、免疫组织化学（IHC）、免疫荧光（IF）等多种免疫学检测技术中，也可以用于后续开发诊断或治疗与DAP12信号通路异常相关的疾病的靶向药物或诊断试剂。

光激化学发光检测尿液样本中磷酸化tau蛋白的试剂盒

Resumen de: CN122814921A

本发明涉及生物医学检测技术领域，提供一种光激化学发光检测尿液样本中磷酸化tau蛋白的试剂盒，包括：供体微球，标记有抗人tau蛋白抗体；受体微球，标记有抗磷酸化tau蛋白抗体；供体微球和所述受体微球用于光激化学发光免疫分析。本发明的试剂盒采用双抗体夹心光激化学发光免疫分析法，通过供体微球与受体微球的协同作用产生化学发光信号，实现尿液样本中磷酸化tau蛋白的定量检测，具有均相检测、操作简便的特点。

用于T细胞疗法的诊断方法

Resumen de: WO2016191755A1

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

GFAP的检测方法、辅助阿尔茨海默病的诊断的方法、以及用于它们的试剂盒

Resumen de: WO2025182761A1

Provided is a method for detecting GFAP in a sample by immunoassay, the method including a first step for forming a complex of a first antibody and GFAP, and a second step for forming a complex of a second antibody and GFAP, the first antibody binding to a region consisting of amino acids at positions 111 to 115 in the amino acid sequence of GFAP.

プロテオマイナー技術を使用したＡＡＶの宿主細胞タンパク質分析

Resumen de: JP2026531970A

0001 本開示は、ウイルスベクターを含有する試料中の少なくとも１つの宿主細胞タンパク質（ＨＣＰ）不純物を濃縮する、同定する、および／または特性評価するための方法を提供する。ＨＣＰ不純物は、ビーズベースのペプチドリガンドのライブラリーの利用を介して濃縮することができる。濃縮したＨＣＰは、続いて、酵素消化に供されてペプチドを生成し、このペプチドを液体クロマトグラフィー－質量分析（ＬＣ－ＭＳ）によって同定して、当該少なくとも１つのＨＣＰ不純物を特異的に同定するおよび／または特性評価することができる。 【選択図】図１Ａ

ＣＮＳ由来のタウペプチドを検出するための血漿アッセイ

Resumen de: WO2025037271A1

Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from subjects, involving the use of a capture antibody that binds to a tau epitope, and a detection antibody that binds to an epitope comprising amino acids residues that span the junction of Exon 4 and Exon 5 of CNS-derived tau.

低骨量または低骨量リスクの検査方法

Resumen de: JP2026149362A

0001 【課題】被験者の糞便中の細菌の情報に基づき、低骨量又は低骨量リスクを検査する方法を提供する。 【解決手段】被験者の糞便中細菌におけるセガテラ・コプリの存在比率を取得する工程を含む、低骨量又は将来の低骨量リスクの検査方法。 【選択図】なし

SYSTEMS FOR IDENTIFYING PROTEOFORMS OF TAU PROTEIN

Resumen de: US20260287600A1

0000 Methods, reagents, kits and systems for analyzing different proteoforms of proteins of interest are provided. The provided methods, systems, etc. provide detection, characterization and quantitation of proteoforms for different biologically relevant proteins for monitoring and characterizing biological processes.

METHODS FOR THE ASSESSMENT OF RISK AND TREATMENTS FOR LIVER CANCERS AND LETHAL LIVER DISEASE COMPLICATIONS

Resumen de: US20260287589A1

0000 Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.

POTENCY ASSAY MATRIX FOR NEURONAL CELLS

Resumen de: US20260287576A1

0000 The invention provides, in some embodiments, a potency assay matrix for assessing potency of dopaminergic neuronal progenitor cells (DANPCs) that are intended for use in treating a neurodegenerative disease such as Parkinson's Disease. The potency assay matrix can include a bioassay for L-DOPA decarboxylase (DDC) activity. In addition to the DDC activity assay matrix, the potency assay matrix may also include one or more additional mechanism of action-based assays such as bioinformatics-based assays for determining whether the DANPCs are dopaminergic neuronal progenitor cells, for determining whether the DANPCs are likely to engraft when implanted into a subject brain, and for determining whether neuronal cells that are derived from the DANPCs are likely to produce dopamine after implantation.

A METHOD FOR REFINED STAGE CLASSIFICATION AND DIAGNOSIS OF A HEREDITARY NEURODEGENERATIVE DISEASE

Resumen de: WO2026196014A1

The invention relates to a method for refined stage classification of a hereditary, preferably monogenic, neurodegenerative diseases mediated by an impairment of a disease-mediating gene, in disease-affected subjects. The invention also relates to diagnosis of a patient with the neurodegenerative diseases comprising classifying said patient in a stage of said disease. The subgroups react differently to treatment. In summary, the present inventors used a preclinical induced neuronal model to predict drug effectiveness in clinical trials, and have found a new dimension on prescreening patients before entering in clinical trials, thereby reducing the trial's failure.

Spatial Proteomics Analysis Using Wavelength-Specific Click Chemistry for Subcellular Resolution Localization

Resumen de: US20260287593A1

The present invention provides methods and systems for antibody-independent spatial proteomics analysis using wavelength-specific click chemistry. Photoactivatable click chemistry reagents responsive to distinct wavelengths (UV, blue, green, red) are introduced into biological samples and selectively activated using laser matrix systems with submicron spatial control. Wavelength-specific activation enables simultaneous labeling of proteins at multiple subcellular locations or tissue regions, followed by mass spectrometry analysis to determine spatial protein distributions with subcellular resolution. The technology eliminates antibody dependencies while providing comprehensive proteome coverage (1000+ proteins per spatial region) at significantly reduced cost and time compared to conventional methods. Applications include clinical cancer diagnostics, drug discovery screening, and research applications across diverse biological systems including cell cultures, tissue sections, and FFPE clinical specimens.

Chemical Carbonylation of Arginine in Peptides and Proteins

Resumen de: US20260285900A1

Disclosed herein are methods of oxidizing a guanidine group comprising contacting a compound or peptide having a guanidine group with a 9,10-phenanthrenequinone or derivative providing compound with an aldehyde group in place of the guanidine group. In certain embodiments, the guanidine group is an arginine amino acid within a protein. In certain embodiments, this disclosure relates to compositions comprising 9,10-phenanthrenequinone derivatives as provided herein.

VERSATILE IMMUNODIAGNOSTIC SMARTPHONE-BASED TOOL FOR ASSESSMENT

Resumen de: WO2026198565A1

A method and related system for immunodiagnostic assessment of an antigen in a sample. A sample is mixed in a sample tube (i.e., cartridge) with magnetic beads and first visualization reagent which are both conjugated with antibodies for the antigen and, if the sample includes the antigen, forms magnetic immunocomplexes. The sample tube is attached to a base having a visualization chamber, the sample is flowed into the base from the sample tube, and the magnetic beads and, if formed, the magnetic immunocomplexes are advanced into the visualization window. A second visualization reagent adapted to react with the first visualization reagent to produce a visible change is introduced. An image is acquired of the visualization window with a smartphone to assess whether the visible change has occurred. The image of the visualization window acquired using the smartphone is evaluated to assess whether the antigen is present in the sample.

PROGNOSTIC AND PREDICTIVE VALUE OF ENDOTHELIAL DYSFUNCTION BIOMARKERS IN SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY

Resumen de: US20260287596A1

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the invention relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, receiving a dataset comprising biomarker concentrations, wherein the dataset is from a sample obtained from a pediatric patient having at least one indication of septic shock, then determining whether the biomarker concentrations of each of the at least one biomarkers are greater than one or more pre-determined cut-off biomarker concentration, wherein the level of said biomarker correlates with a predicted outcome.

METHODS OF DETECTING MULTIPLE DISEASE BIOMARKERS

Resumen de: WO2026193586A1

Disclosed herein are methods of detecting at least two biomarkers in a DNA sample from a subject, the method comprising simultaneously, in a single test, amplifying the regions of DNA containing each of the at least two types of biomarkers in the DNA sample to produce amplified DNA; sequencing, by a sequencer, the amplified DNA to produce a sequencing read; and wherein the sequencing read identifies a presence and/or an absence of the at least two types of biomarkers, optionally, outputting a report indicating the presence or absence of the at least two types biomarkers in the DNA sample wherein the at least two types of biomarkers are selected from: (i) single nucleotide variations (SNVs), and/or insertion or deletion (indel) mutations; (ii) chromosomal copy number variations (CNVs), and (iii) gene CNVs.

BINDING MOLECULES TARGETING METHYLPSEUDOURIDINE

Resumen de: WO2026198475A1

The present invention relates to an antigen-binding molecule specifically binding to methylpseudouridine or 1-methyluracil, a polynucleotide encoding it, a conjugate comprising it, and a method for producing such an antigen-binding molecule. The invention further relates to a method for detecting methylpseudouridine or 1-methyluracil, a method for detecting and/or quantifying a level of methylpseudouridine and/or 1-methyluracil, a kit for detecting presence and/or for quantifying a level of methylpseudouridine and/or 1-methyluracil, and a kit for enriching or purifying methylpseudouridine or polynucleotides containing methylpseudouridine.

High-sensitivity Assay for Serum Neurofilament Light Chain

Resumen de: US20260287580A1

0000 The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from disease such as a neurological condition or disease. In general, detection or measurement of one or more biomarkers, such as neurofilament light chain (NfL), and combinations thereof with assays of the present disclosure, assists in the identification of disease such as neurological disease. The present disclosure also provides methods for selecting patients for treatment of neurological disease.

ANTIGEN COMBINATION AND METHODS AND USES THEREOF

Nº publicación: AU2025226208A1 24/09/2026

Solicitante:

MACFARLANE BURNET INST FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED
MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED

Resumen de: AU2025226208A1

The present invention relates to an antigen combination comprising Treponema pallidum (Tp) antigens. The present invention also relates to vectors, polynucleotides, host cells and methods for producing such antigen combinations. The present invention also relates to method and uses of such antigen combinations. The present invention also relates to compositions, assays and kits and the methods and uses thereof.